ArticleAllergy2023
Clinical and laboratory features of patients diagnosed with alpha-gal syndrome-2010-2019.
Article in Allergy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens.The Journal of clinical investigation · 2026Article
- Alpha-Gal Syndrome Is More than Meats the IgE: A Patient Survey of Symptoms, Diagnosis, and Burdens.Healthcare (Basel, Switzerland) · 2026Article
- Perioperative Considerations for Alpha-Gal Syndrome: A Literature Review and Single-Center Experience in a Highly Endemic Area.Diseases (Basel, Switzerland) · 2026Review
- Immunogenic and cross-reactive carbohydrate determinants in ticks and other arthropods.Journal of applied biomedicine · 2026Review
- Misdiagnosis of alpha-gal syndrome as non-celiac gluten sensitivity or lactose intolerance: A diagnostic blind spot for clinicians.World journal of gastroenterology · 2026Review
- Nutritional considerations for alpha-gal syndrome: a mini-review.Frontiers in allergy · 2026Review
- Childhood-onset alpha-gal syndrome in the central black sea region: real-world data on diagnostic delays, age-specific clinical patterns, environmental risk factors, and anaphylaxis predictors.European journal of pediatrics · 2025Article
- Ticked Off: Allergic Effector Cells in the Pathogenesis of Alpha-gal Syndrome.Current allergy and asthma reports · 2025Review
- A Review of Alpha-Gal Syndrome for the Infectious Diseases Practitioner.Open forum infectious diseases · 2025Review
- Article
- Use of over-the-counter antiallergic products-analysis of sales data in Poland from 2020 to 2023.Frontiers in pharmacology · 2025Article
- Allergenic potency of various foods of mammalian origin in patients with α-Gal syndrome.Allergy · 2025Article
- Increasing prevalence of galactose-α-1,3-galactose sensitization in the Danish general adult population.Allergy · 2025Article
- Alpha-Gal Syndrome: An Underrated Serious Disease and a Potential Future Challenge.Global challenges (Hoboken, NJ) · 2024Review
- Review
- The α-Gal epitope - the cause of a global allergic disease.Frontiers in immunology · 2024Review
- Alpha-gal syndrome-Food or drug allergy: A case report.Clinical case reports · 2023Article
- Clinical and laboratory features of patients diagnosed with alpha-gal syndrome-2010-2019.Allergy · 2023Article
- Digital Health Solutions for Alpha-Gal Syndrome: A Scoping Review of Telemedicine Evidence and Applications.Missouri medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlpha-gal syndrome (AGS) is an IgE-mediated allergy to galactose-alpha-1,3-galactose. Clinical presentation ranges from hives to anaphylaxis; episodes typically occur 2-6 h after exposure to alpha-gal-containing products. In the United States, lone star tick bites are associated with the development of AGS. To characterize features of AGS, we evaluated a cohort of patients presenting for care at the University of North Carolina, focusing on symptoms, severity, and identifying features unique to specific alpha-gal-containing product exposures.
methodsWe performed a chart review and descriptive analysis of 100 randomly selected patients with AGS during 2010-2019.
resultsMedian age at onset was 53 years, 56% were female, 95% reported White race, 86% reported a history of tick bite, and 75% met the criteria for anaphylaxis based on the involvement of ≥2 organ systems. Those reporting dairy reactions were significantly less likely to report isolated mucocutaneous symptoms (3% vs. 24%; ratio [95% CI]: 0.1 [0.1, 0.3]) than those who tolerated dairy, and were more likely to report gastrointestinal symptoms (79% vs. 59%; ratio [95% CI]: 1.3 [0.7, 2.6]), although this difference was not statistically significant. Dairy-tolerant patients demonstrated higher alpha-gal sIgE titers (as a percentage of total IgE) than dairy-reactive patients (GM 4.1 [95% CI: 2.7, 6.1] vs. GM 2.5 [95% CI: 1.3, 4.8], respectively; ratio -1.6 [95% CI: -1.0, 3.9]).
conclusionWhile tick exposure is common in the southern United States, nearly all AGS patients reported a tick bite. Gastrointestinal symptoms were prominent among those reporting reactions to dairy. Anaphylaxis was common, underscoring the severity and need to raise awareness of AGS among patients and providers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.